Meta-analysis supports association between metabolic syndrome and hypogonadism; testosterone therapy may improve metabolic control and reduce central obesity
Testosterone and metabolic syndrome: a meta-analysis study. Corona G, Monami M, Rastrelli G, et al. J Sex Med 2011;8(1):272−283.
A systematic review and meta-analysis of available prospective and cross-sectional studies comparing androgen levels in men with or without metabolic syndrome (MetS) was performed to analyse the relationship between androgen levels and MetS.1 Additionally, a separate meta-analysis of available randomized controlled trials reporting the metabolic effects of testosterone therapy was performed. Overall, 21 quality studies were included; 13 cross-sectional, 3 longitudinal and 4 randomized controlled published trials, and 1 unpublished randomized controlled trial. Data for 2,254 men with and 6,407 men without MetS were included.
What is known
A group of interrelated factors, including abdominal obesity, insulin resistance, impaired glucose tolerance, dyslipidaemia and hypertension have become known as the metabolic syndrome (MetS).2 Although various diagnostic definitions have been proposed and there has been controversy over whether the MetS should be considered an independent syndrome, there is evidence that MetS is associated with a doubling of the 5- to 10-year risk of cardiovascular diseases and a 5-fold increase in the risk of T2DM.2 In addition, there is a large body of evidence that erectile dysfunction (ED) and male hypogonadism are often related to MetS,3-5 and that ED may be predictive of the presence of MetS.6There also is emerging evidence that hypogonadism and ED are surrogate markers predicting metabolic and cardiovascular events.7−11
The presence of hypogonadism and ED in men with MetS may therefore signal to healthcare professionals that specific lifestyle changes (weight loss, physical exercise) or pharmacological interventions (testosterone replacement) may be beneficial to delay progression to a higher cardiovascular and metabolic risk category. Furthermore, testosterone therapy has been shown to improve insulin resistance, glycaemic control, central obesity, lean body mass, hypercholesterolaemia and pro-inflammatory cytokines associated with diabetes, atherosclerosis and MetS.12-15However, there have been few randomised, controlled studies specifically evaluating whether testosterone therapy benefits MetS in hypogonadal men.
What this study adds
This meta-analysis of available randomised controlled trials comparing testosterone levels in subjects with or without MetS confirmed that testosterone therapy is able to improve central obesity and other factors related to insulin resistance in subjects with MetS. In particular, the meta-analysis provided evidence of a reduction in visceral adiposity and HOMA-IR, as well as fasting glycaemia and triglyceride levels. Although confirmation through large placebo-controlled trials is required, it is hypothesized that testosterone therapy might contribute to an improvement in the efficacy of treatments for MetS by reducing visceral adiposity. However, the relatively short duration of the available randomised controlled trials and the limited number of patients enrolled means that these findings should be treated with caution.
The evaluation of available cross-sectional and longitudinal studies also provided additional support for an independent relationship between MetS and hypogonadism, regardless of the way MetS is defined. MetS is significantly associated with an overall lower total testosterone level of over 2 nmol/L, with the difference more apparent in men with, rather than without, erectile dysfunction. The findings suggest that testosterone level may be a useful indicator of metabolic status in men with erectile dysfunction.